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It has been recently shown that Toll-like receptor4 mediated nuclear factor κB (TLR4–NF-
κB) signaling plays a critical role in the pathogenesis of rheumatoid arthritis mediated by pro-
inflammatory cytokines in arthritic synovium. Here we evaluate the therapeutic potential of 
glycol-split non-anticoagulant heparin/D-erythro-sphingosine nanoparticles (NAHNPs), 
which have shown strong inhibitory effect against TLR4 induced inflammation, in an 
experimental arthritis model. NAHNP significantly inhibited the production of pro-
inflammatory cytokines such as TNF-α, IL-6 and IL-1β in lipopolysaccharide (LPS)-induced 
primary mouse macrophages and DC2.4 dendritic cell line. The nanoparticles were 
administered to type II collagen-induced arthritis (CIA) mice by intraarticular injections once 
per day starting from onset of the disease symptoms. Treatment with NAHNP had a potent 
suppressive effect in CIA mice, observed with a decrease in arthritis score and footpad 
swelling. The animals treated with NAHNP significantly reduced levels of IgG1 and IgG2a 
antibodies against bovine type II collagen. Levels of proinflammatory cytokines — e.g., TNF-
α, IL-6 and IL-1β in knee joints and sera were significantly inhibited compared to control 
mice. Moreover, nuclear localization of RelA in knee joints was significantly inhibited in 
NAHNP treatment, indicating down-regulation of the NF-κB signaling pathway. In addition, 
histological examination revealed significant suppression of inflammatory cell infiltration, 
joint destruction and synovial proliferation in synovium compared with control mice. These 
results suggest that selective inhibition of TLR4–NF-κB signaling with lipid modified heparin 
derivatives composited to nanostructures provides an effective therapeutic approach to inhibit 















The involvement of toll-like receptors (TLRs) in the pathogenesis of rheumatoid arthritis is 
supported by an increasing number of studies [1–7]. Notably, expression of TLR4 is highly 
increased in the synovium of rheumatoid arthritis patients [8, 9] and TLR4 mutant mice are 
protected from experimental arthritis [10–12]. It is thought that extracellular endogenous 
ligands present in the arthritic joints activate TLR4 and contribute to maintaining 
inflammation [2, 3, 6, 13–15]. Recently, it was demonstrated that during arthritis, immune 
complexes containing citrullinated proteins greatly increase inflammation through a myeloid 
differentiation factor 88 (MyD88)-dependent pathway via TLR4 and activated Fcγ receptors 
[16]. Signaling activated by TLR4 ligands induces proinflammatory cytokine expression from 
TLR4-overexpressing cells such as macrophages, dendritic cells and fibroblasts in arthritic 
synovium [17]. Furthermore, TLR4 expressed on CD4+ T cells promotes autoimmune 
inflammation [18]. The generation of cytokines such as TNF-α, IL-6 and IL-1β regulated by 
transcription factor nuclear factor κB (NF-κB) is important in the pathogenesis of rheumatoid 
arthritis. Systemic inhibition of these cytokines with biologic drugs is effective as a short-term 
treatment but might also suppress the whole immune system and increase infection risk [19]. 
Evidence supports a role for TLR4 in the pathogenesis of rheumatoid arthritis, thus targeting 
the receptor of cell populations secreting distinct cytokines might be an effective approach to 
suppressing inflammation. We recently developed nanoparticles composed of heparins 
conjugated with D-erythro-sphingosine which blockade TNF-α production from Escherichia 
coli lipopolysaccharide (LPS)-induced macrophages. The conjugates form stable self-
assemblies, and thus might be promising candidates for in vivo drug delivery and therapeutics 
[20]. Anti-inflammatory effect of heparin has been widely described in the literature although 
the mechanisms responsible for the effects are complex and incompletely understood [21]. 
The primary role of heparin as an anti-inflammatory agent was closely linked to its ability of 
binding and inhibiting proteins such as selectins and growth factors involved in inflammation 
and angiogenesis [22]. We found that unlike native heparin, heparins modified with lipids and 
composited to nanostructures act as selective TLR4 antagonists and have much greater anti-
inflammatory activity. In vitro studies showed that glycol-split non-anticoagulant heparin/D-
erythro-sphingosine nanoparticles (NAHNPs) suppressed the production of TNF-α from LPS-
stimulated macrophages by inhibiting TLR4-mediated NF-κB signaling with an IC50 of 0.019 
mg/mL. This suggests that the heparin nanoparticles can block the activation of TLR4-
overexpressing primitive immune cells such as macrophages and dendritic cells in arthritic 
synovium which is a different target of heparin from that of the above-mentioned activity. In 
this context, the present study investigated the potential anti-inflammatory effect of NAHNPs 
in the collagen-induced arthritis model. First, we tested the inhibitory potency of NAHNPs on 
the production of proinflammatory cytokines from LPS-stimulated macrophages and dendritic 
cells. Next, we studied the therapeutic activity of these nanoparticles in a mouse model of 
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collagen-induced arthritis (CIA). We discuss these findings and potential benefits of these 
nanoparticles as a novel specific treatment for rheumatoid arthritis.  
 
2. Materials and methods 
 
2.1. Preparation of NAHNPs 
Nanoparticles were prepared as described previously [20]. First, glycol-split non-
anticoagulant heparin (NAH) was obtained by periodate-oxidation and borohydride-reduction 
of heparin (Product ID X1009996-8, Mw 14 kDa, Nacalai Tesque, Inc., Kyoto, Japan) 
according to the method of Conrad and Guo [23]. NAH (0.1 g) then was dissolved in 
formamide (5 mL) with 40 mg 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide followed by 
the addition of 5mL dimethyl formamide containing 5 mg D-erythro-sphingosine (LKT 
Laboratories, Inc., St. Paul, MN). The reaction mixture was stirred at room temperature for 24 
h under a nitrogen atmosphere. Afterwards, the reaction mixture was precipitated in pure 
ethanol, centrifuged at 14,000 ×g for 10 min followed by decantation. This was repeated 3 
times to remove any remaining unreacted D-erythro-sphingosine and reaction solvents. 
Precipitates were then dried in a vacuum and lyophilized as NAHNP. Nanoparticles were 
prepared by ultrasonication of NAHNP using a probe sonicator (UD-201, Tomy Seiko Co. 
Ltd., Japan) for 1min at 20 kHz and 50 W/cm2 in distilled water. For comparison, heparin 
was used without oxidative ring-opening reactions to synthesize native heparin nanoparticles 
(HPNPs). We used NAHNP and HPNP having the degree of D-erythro-sphingosine 
substitution of 4.2% and 6.3%, respectively, to keep their particle sizes comparable with each 
other (~150 nm) [20]. It should be noted that the particle size (or degree of D-erythro-
sphingosine substitution) is not a critical determinant in anti-inflammatory effect in LPS-
stimulated peritoneal-elicited macrophages [20]. 
 
2.2. Cell culturing and in vitro assay for cytokines 
Mouse peritoneum-derived macrophages were received as described previously [24]. Briefly, 
macrophages were harvested from 5-week-old female ICR mice 4 days after intraperitoneal 
injection of 1 mL 2.9% thioglycolate medium (Nissui Pharmaceutical, Tokyo, Japan). Cells 
were washed and cultured in RPMI 1640 medium supplemented with 10% fetal bovine serum 
(FBS) (Flow Laboratories, Irvine, UK), penicillin G (100 U/mL), and streptomycin (100 
μg/mL), and then seeded on 24-well plates (Becton Dickinson, Lincoln Park, NJ) at a density 
of 1.5 × 105 cells per well. Non-adherent cells were washed with phosphate buffered saline 
(PBS) after incubation for 2 h at 37 °C in a humidified atmosphere with 5% CO2. The 
remaining cells were cultured for 24, 48 or 72 h. After replacing the media with Opti-MEM® 
I Reduced Serum Medium (Gibco®, Life Technologies, Rockville, MD) cells were stimulated 
with LPS (Sigma-Aldrich, St Louis, MO) at final concentration of 20 ng/mL with or without 
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nanoparticles at final concentration of 0.5mg/mL and incubated for 24 h. The supernatants 
were assayed for cytokines. DC2.4 cells, a murine dendritic cell line, were grown in complete 
media RPMI 1640 as described above and were maintained at 37 °C in a humidified incubator 
with 5% CO2. Cells were maintained via weekly passage and utilized for experimentation at 
80–90% confluency. Cells were stimulated with LPS (20 ng/mL) for 24 h in Opti-MEM® I 
Reduced Serum Medium with or without nanoparticles (0.5 mg/mL) and the supernatants 
were assayed for cytokines. Cytokines were quantified using mouse TNF-α, IL-6 and IL-1β 
ELISA kits (eBioscience, Inc., San Diego, CA) following the manufacturer's instructions. 2.3. 
Induction and assessment of arthritis Mice were obtained from Shizuoka Agricultural 
Cooperative Association for Laboratory Animals (Shizuoka, Japan). All animal experiments 
were performed in accordance with the Principles of Laboratory Animal Care as directed by 
the U.S. National Institutes of Health and the Guidelines for Animal Experiments of Kyoto 
University. Bovine type II collagen (4 mg/mL final concentration) (Elastin Products Co., 
Owensville, MO) was dissolved in 0.1 M acetic acid at 4 °C overnight and then emulsified 
with an equal volume of complete Freund's adjuvant containing 4 mg/mL Mycobacterium 
tuberculosis. Male 8-week-old DBA/1J mice were immunized subcutaneously at the base of 
the tail with 100 μL of the emulsion. At day 21 from primary immunization, mice were 
boosted intraperitoneally with 100 μL of bovine type II collagen emulsion prepared with 
incomplete Freund's adjuvant. NAHNP (20 mg/kg per animal) was administered by 
intraarticular injections to both knees once per day starting from day 28 until day 50 from 
primary immunization. Arthritis was assessed blindly using four paws per mouse using the 
following scores: 0, normal (no swelling); 1, mild/moderate erythema and swelling of paws 
and/or multiple digits; 2, swelling and severe erythema; and 3, swelling of all joints and 
ankylosis. Paw swelling was assessed by measuring the thickness of affected paws with 
calipers. Tissue TNF-α, IL-6 and IL-1β levels were measured using ELISA kits (eBioscience, 
Inc., San Diego, CA). Serum cytokines were measured using a flow cytometric bead array 
mouse inflammation kit (BD Biosciences, San Jose, CA).  
 
2.4. Determination of anti-type II collagen immunoglobulins 
Serum samples were stored in aliquots at −80 °C until they were used for ELISA assay. 
Ninety-six-well immunoplates (Nunc® Maxisorp, Thermo Scientific, Roskilde, Denmark) 
were coated overnight with 5 μg/mL of bovine type II collagen in PBS at 4 °C. Nonspecific 
binding was blocked with 2% of bovine serum albumin (BSA) in PBS at room temperature 
for 2 h. Diluted serum samples (in 0.2% BSA in PBS containing 0.05% Tween-20) were 
added and incubated for 2 h at room temperature. Serum dilutions were chosen after 
preliminary assays and ranged from 1:500 to 1:20,000 for IgG1, and from 1:5000 to 1:50,000 
for IgG2a. The plates were then incubated with horseradish peroxidase-conjugated goat anti-
mouse IgG1 or IgG2a (Abcam Inc., Cambridge, MA) for 1 h. 3,3′,5,5′-Tetramethylbenzidine 
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solution was used as a substrate and the optical density was measured using an ELISA reader 
(Eon Microplate Spectrophotometer, Biotek Instruments, Winooski, VT) at 450 nm. All 
incubations were made with a volume of 100 mL/well. Plates were washed 3 times with 250 
mL PBS containing 0.05% Tween-20 between steps. The anti-type II collagen concentrations 
were determined by reference to standard curves generated using murine anti-bovine type II 
collagen IgG1 and IgG2a (Chondrex, Inc., Redmond, WA).  
 
2.5. NF-κB activation assay 
Nuclear RelA levels were measured using a TransAM® NF-κB p65 kit (Active Motif, 
Carlsbad, CA). Knee joints were dissected and cleaned from soft tissues. The tissue was 
homogenized in cold phosphate buffered saline (0.5 g tissue in 1 mL) and centrifuged at 
14,000 ×g for 3min at 4 °C. The supernatant was then collected for analysis of cytokine levels. 
The remaining pellet was used for preparation of nuclear extracts using a TransAM® Nuclear 
Extract Kit (Active Motif, Carlsbad, CA) following the manufacturer's instructions. The 
samples were stored at −80 °C until analyzed. 2.6. Histology of knee joints for histological 
analysis, mice were sacrificed by cervical dislocation at day 50 after first immunization. Knee 
tissues were randomly collected, then fixed with 10% paraformaldehyde, decalcified in 5% 
formic acid and embedded in paraffin. Next, 7 μm sections were stained with hematoxylin 
and eosin (H&E). Histopathological changes were scored using the following parameters: 
inflammation — 0 (normal) to 4 (severe inflammation with necrosis and edema), and joint 
destruction—0 (normal) to 4 (severe extensive areas of cartilage ulcerations). 
 
2.7. Statistics 
GraphPad Prism 5.0 (GraphPad Software, Inc.) was used to perform statistical tests. 
Experiments involving two groups were analyzed by two-tailed, unpaired t test. Statistical 
analysis of in vivo data was performed by one-way ANOVA. P b 0.05 was considered 




3.1. Inhibition of LPS-induced production of cytokines from macrophages and dendritic cells 
We recently demonstrated that NAHNP suppresses TNFα production in primary cultured 
mouse macrophages. Specifically, nanoparticles prepared from glycol-split heparin were more 
potent than those of prepared from native heparin in vitro [20]. Here, NAHNP was evaluated 
for its potential to inhibit IL-6 and IL-1β production from macrophages following LPS 
stimulation. Cells were challenged to LPS with or without NAHNP and supernatants 
quantified for cytokines. As expected, the nanoparticles significantly inhibited IL-6 and IL-1β 
levels (Fig. 1A). In a separate experiment, removal of NAHNP from the medium after 1-h 
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pretreatment but prior to LPS stimulation also resulted in significant suppression of cytokines 
after additional 24-h LPS exposure (data not shown). Besides macrophages, dendritic cells 
activated via TLR4 produce a variety of cytokines such as TNF-α, IL-6, and IL-1β. Therefore, 
we evaluated the anti-inflammatory effect of NAHNP using DC2.4 cells, a murine dendritic 
cell line. DC2.4 cells were stimulated with LPS and simultaneously treated with NAHNP. The 
addition of LPS resulted in increased production of TNF-α, IL-6 and IL-1β. NAHNP blocked 
the production of all cytokines tested (Fig. 1B). When not stimulated with LPS but only 
treated with NAHNP (0.5 mg/mL), neither macrophage nor DC2.4 cells produce TNF-α, IL-6 
or IL-1β above their basal levels (data not shown).  
 
3.2. Inhibition of arthritis 
Mice immunized with bovine type II collagen (CII) to induce CIA received daily 
intraarticular injections of NAHNP (20 mg/kg in total to both knees) from disease onset (day 
28). Nanoparticles prepared with native heparin/D-erythro-sphingosine conjugates (HPNP) 
were used for comparison. Long-term administration of HPNP ameliorated arthritis in some 
mice, which was not statistically significant compared to the CIA group (Fig. 2A), and 
induced knee hemorrhoids due to anticoagulation. NAHNP significantly (P b 0.05 compared 
with the CIA group) inhibited the development of arthritis (Fig. 2A) and reduced paw 
swelling (P b 0.01 compared with the CIA group) (Fig. 2B). 2-[(Amino-carbonyl) amino]-5-
(4-fluorophenyl)-3-thiophene-carboxamide (TPCA-1), a selective IκB kinase 2 inhibitor, was 
applied as a positive control (20 mg/kg intraperitoneally [25]) (Fig. 2C). Quantification of 
major proinflammatory cytokines in knee tissue on days 35 and 45 revealed that TNF-α, IL-6 
and IL-1β were markedly decreased (Fig. 3A). Nuclear localization of RelA in knee tissue 
extracts was significantly inhibited in NAHNP treated mice compared to controls (Fig. 3B). 
Synchronously with tissue cytokines, NAHNP decreased sera TNF-α, IL-6 and IL-1β levels 
on days 35 and 50 (Fig. 4). Humoral responses against CII were monitored throughout the 
study. In contrast to marked auto-antibody synthesis in CIA control mice, surprisingly, 
NAHNP-treated mice showed a rapid decrease of antibody titers from the first day of 
treatment (Fig. 5A and B) indicating a systemic effect despite local administration. The effect 
of NAHNP treatment on joint destruction was further confirmed with histological analysis of 
knee joints. Joints from NAHNP-treated mice showed a remarkable improvement in 
inflammatory cell infiltration, joint destruction and synovial proliferation compared with CIA 
controls (Fig. 6). Thus, the mechanism underlying NAHNP-induced suppression of CIA was 
likely to involve the complex inhibition of production of proinflammatory cytokines, i.e., 
TNF-α, IL-6 and IL-1β, induced by the TLR4-mediated NF-κB pathway and suppression of 






We previously developed nanoparticles self-assembled from the amphiphilic conjugates of 
glycol-split non-anticoagulant heparin/D-erythro-sphingosine (NAHNP) and analyzed their 
stability for further in vivo drug targeting [20]. The nanoparticles ranged from110 to 160 nm. 
Interestingly, we found that these nanoparticles effectively blocked LPS-stimulated TNF-α 
production from macrophages in vitro. The anti-inflammatory effect was mediated through 
inhibition of the TLR4–NF-κB signaling pathway. The present study was initiated to examine 
the anti-arthritic activity of NAHNP, since inhibition of pro-inflammatory cytokines and 
transcription factors activated during inflammation is essential for effective disease-
modifying anti-rheumatic drugs [19]. In vitro studies showed that NAHNP blocks the 
production pro-inflammatory cytokines from LPS-stimulated macrophages and dendritic cells 
by inhibiting TLR4-mediated NF-κB signaling. In rheumatoid arthritis, macrophages and 
dendritic cells overproduce proinflammatory cytokines, mainly TNF-α, IL-1β and IL-6, which 
is a pivotal event leading to chronic inflammation [4, 26]. These cytokines are controlled by a 
transcription factor NF-κB [27]. Analysis of nuclear extracts from arthritic synovial tissue 
revealed the presence of increased NF-κB DNA binding activity [28, 29].We found that 
NAHNP significantly inhibited most pro-inflammatory cytokines, including TNF-α, IL-1β 
and IL-6 in vivo. Broad-spectrum cytokine inhibition successfully reduced disease severity 
and cartilage destruction in CIA. Furthermore, NAHNP targeted TLR4 to suppress the nuclear 
localization of RelA in vivo. It was demonstrated that arthritis severity is associated with high 
humoral responses to antigens [30, 31]. Antigen-auto-antibody complexes induce cytokine 
production by macrophages through the synergistic activation of TLR4 and Fcγ receptors [16, 
32]. Measurement of circulating autoantibodies in treated mice revealed that NAHNP 
inhibited IgG1 and IgG2a antibody isotypes. Our data supports the notion that antigen-
immune complex-mediated inflammation in rheumatoid arthritis may be promoted by 
augmented specific signaling pathways via innate immune receptors such as TLR4–NF-κB [7, 
16, 32–34]. Drug delivery systems such as liposomes [35–37], albumin microspheres [38], 
gelatin/chondroitin 6-sulfate [39] and polylactic acid/polyglycolic acid copolymer particles 
[40, 41] have been developed to inject into the articular joints. These particulate carriers are 
assumed to stay for long in the articular cavity and increase drug residence time following the 
intra-articular administration [42, 43]. It has also been known that particles can penetrate into 
the cartilage (b50 nm) [44] or be phagocytosed by macrophages [42] depending on their size. 
Heparin nanoparticles having a size of ~150 nm are supposed to reside long-term in the cavity 
as other particles can basically do; however, detailed pharmacokinetic investigation will be 







In conclusion, we show that hydrophobically modified glycol-split heparin nanoparticles 
exhibit anti-inflammatory effects and suppress an animal model of CIA. This effect is 
mediated through the inhibition of the TLR4–NF-κB signaling. Pharmacological activity of 
the nanoparticles was associated with suppression of complex pro-inflammatory cytokines 
in joints and sera, as well as suppressed levels of autoantibodies. Thus, selective inhibition of 
TLR4–NF-κB signaling with NAHNP provides an effective therapeutic approach to inhibit 
chronic inflammation in an animal model of rheumatoid arthritis. However, additional 
pharmacological and toxicological studies are required to evaluate whether the nanoparticles 
can be used in clinical settings.  
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Figure 1 Effect of NAHNP on LPS-induced production of proinflammatory 





























Figure 3 Effect of NAHNP on NF-B activity and proinflammatory cytokine 





Figure 4 Effect of NAHNP on serum TNF-, IL-6 and 
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Figure 1 Effect of NAHNP on LPS-induced production of proinflammatory cytokines by 
primary macrophages and DC2.4 cells. (A) Quantification of IL-6 and IL-1β from peritoneal 
macrophages isolated from ICR mice. Cells (1.5×10
5
 cells per well) were seeded to 24-well-
plates and were not treated (NT) or stimulated with LPS (20 ng/mL) for 24 h in the presence 
or absence of NAHNP (0.5 mg/mL). (B)DCs (1.5×10
5
 cells per well) were seeded to 24-well-
plates and were treated with 0.5 mg/mL of NAHNP and/or 20 ng/mL LPS. Supernatants were 
collected after 24 h and assayed for cytokines production. Data are shown as mean SEM 
(n=3). * P 0.05, ** P  0.01. 
 
 
Figure 2 Therapeutic effect of NAHNP on CIA. Artistic severity score (A) and hind paw 
swelling (B) of male DBA/1J mice treated with NAHNP (20 mg/kg per animal) and HPNP 
(20 mg/kg per animal) by intraarticular injections to both knees once per day between days 28 
and 50 (n=10). CIA-induced mice treated with saline. (C) Artistic severity score of mice 
treated with TPCA-1 (20 mg/kg) (n=8). Data represents mean SEM. 
 
Figure 3 Effect of NAHNP on NF-B activity and proinflammatory cytokine accumulation in 
knee tissue. Mice were killed at indicated days and knee tissues from naïve, CIA and NAHNP 
treated mice were dissected and homogenized. (A) Supernatants were analyzed for cytokines 
by ELISA (n=8). (B) Nuclear extracts were assayed for localization of RelA (2 knees per 
animal pooled, n=8 animals). Data represents mean SEM. * P 0.05, ** P 0.01.  
 
Figure 4 Effect of NAHNP on serum TNF-, IL-6 and IL-1β on days 35 and 50 (n=8). Serum 
samples from naïve, CIA and NAHNP treated mice were collected and assayed for cytokines 
as described in Methods. Data represents mean SEM. * P 0.05, ** P 0.01, *** P 0.001. 
 
Figure 5 Effect of NAHNP on serum anti-collagen type II autoantibody isotypes IgG1 (A) 
and IgG2a (B) (n=10per group). Data represents mean SEM. * P 0.01 versus CIA group. 
 
Figure 6 Effect of NAHNP on pathology of CIA mouse knee tissues. Top: H&E sections of 
normal joints (left) and joints of untreated (middle) or (right) NAHNP (20 mg/kg) treated CIA 
mice(day 50). Bottom: cell infiltration, joint destruction and synovial proliferation scores. 











[1] U. Müller-Ladner, T. Pap, R.E. Gay, et al., Mechanisms of disease: the molecular and 
cellular basis of joint destruction in rheumatoid arthritis, Nat. Rev. Rheumatol. 1 (2005) 102–
110. 
[2] M.F. Roelofs, L.A. Joosten, S. Abdollahi-Roodsaz, et al., The expression of toll-like 
receptors 3 and 7 in rheumatoid arthritis synovium is increased and costimulation of toll-like 
receptors 3, 4, and 7/8 results in synergistic cytokine production by dendritic cells, Arthritis 
Rheum. 52 (2005) 2313–2322. 
[3] Q.Q. Huang, R.M. Pope, The role of toll-like receptors in rheumatoid arthritis, Curr. 
Rheumatol. Rep. 11 (2009) 357–364. 
[4] G.S. Firestein, Evolving concepts of rheumatoid arthritis, Nature 423 (2003) 356–361. 
[5] A.N. Theofilopoulos, R. Gonzalez-Quintial, B.R. Lawson, et al., Sensors of the innate 
immune system: their link to rheumatic diseases, Nat. Rev. Rheumatol. 6 (2010) 146–156. 
[6] F.G. Goh, K.S. Midwood, Intrinsic danger: activation of Toll-like receptors in rheumatoid 
arthritis, Rheumatology (Oxford) 51 (2012) 7–23. 
[7] A. Marshak-Rothstein, I.R. Rifkin, Immunologically active autoantigens: the role of toll-
like receptors in the development of chronic inflammatory disease, Annu. Rev. Immunol. 25 
(2007) 419–441. 
[8] T.R. Radstake, Expression of toll-like receptors 2 and 4 in rheumatoid synovial tissue and 
regulation by proinflammatory cytokines interleukin-12 and interleukin-18 via interferon-
gamma, Arthritis Rheum. 50 (2004) 3856–3865. 
[9] C. Ospelt, Overexpression of toll-like receptors 3 and 4 in synovial tissue from patients 
with early rheumatoid arthritis: toll-like receptor expression in early and longstanding arthritis, 
Arthritis Rheum. 58 (2008) 3684–3692. 
[10] J.Y. Choe, B. Crain, S.R.Wu, et al., Interleukin 1 receptor dependence of serum 
transferred arthritis can be circumvented by toll-like receptor 4 signaling, J. Exp. Med. 197 
(2003) 537–542. 
[11] E.K. Lee, S.M. Kang, D.J. Paik, et al., Essential roles of Toll-like receptor-4 signaling in 
arthritis induced by type II collagen antibody and LPS, Int. Immunol. 17 (2005) 325–333. 
[12] M. Pierer, U.Wagner,M. Rossol, et al., Toll-like receptor 4 is involved in inflammatory 
and joint destructive pathways in collagen-induced arthritis in DBA1Jmice, PLoS ONE 6 
(2011) e23539. 
[13] K. Midwood, S. Sacre, A.M. Piccinini, et al., Tenascin-C is an endogenous activator of 
Toll-like receptor 4 that is essential for maintaining inflammation in arthritic joint disease, 
Nat. Med. 15 (2009) 774–780. 
[14] J.S. Park, D. Svetkauskaite, Q. He, et al., Involvement of toll-like receptors 2 and 4 in 




[15] M.F. Roelofs,W.C. Boelens, L.A. Joosten, et al., Identification of small heat shock 
protein B8 (HSP22) as a novel TLR4 ligand and potential involvement in the pathogenesis of 
rheumatoid arthritis, J. Immunol. 176 (2006) 7021–7027. 
[16] J. Sokolove, X. Zhao, P.E. Chandra, et al., Immune complexes containing citrullinated 
fibrinogen costimulate macrophages via Toll-like receptor 4 and Fcγ receptor, Arthritis 
Rheum. 63 (2011) 53–62. 
[17] Y. Tamaki, Y. Takakubo, T. Hirayama, et al., Expression of Toll-like receptors and their 
signaling pathways in rheumatoid synovitis, J. Rheumatol. 38 (2011) 810–820.  
[18] J.M. Reynolds, G.J. Martinez, Y. Chung, et al., Toll-like receptor 4 signaling in T cells 
promotes autoimmune inflammation, Proc. Natl. Acad. Sci. U. S. A. 109 (2012) 13064–13069. 
[19] J.S. Smolen, G. Steiner, Therapeutic strategies for rheumatoid arthritis, Nat. Rev. Drug 
Discov. 2 (2003) 473–488. 
[20] H. Babazada, F. Yamashita, S. Yanamoto, M. Hashida, Self-assembling lipid modified 
glycol-split heparin nanoparticles suppress lipopolysaccharide-induced inflammation through 
TLR4–NF-kB signaling, J. Control. Release (2014), http://dx.doi.org/10. 
1016/j.jconrel.2014.09.011. 
[21] E. Young, The anti-inflammatory effects of heparin and related compounds, Thromb. 
Res. 122 (6) (2008) 743–752. 
[22] D.J. Tyrrell, A.P. Horne, K.R. Holme, J.M. Preuss, C.P. Page, Heparin in inflammation: 
potential therapeutic applications beyond anticoagulation, Adv. Pharmacol. 46 (1999) 151–
208. 
[23] H.E. Conrad, Y. Guo, Structural analysis of periodate-oxidized heparin, Adv. Exp. Med. 
Biol. 313 (1992) 31–36. 
[24] W. Yeeprae, S. Kawakami, F. Yamashita, et al., Effect of mannose density onmannose 
receptor-mediated cellular uptake of mannosylated O/W emulsions by macrophages, J. 
Control. Release 114 (2006) 193–201. 
[25] P.L. Podolin, J.F. Callahan, B.J. Bolognese, et al., Attenuation ofmurine collagen-
induced arthritis by a novel, potent, selective small molecule inhibitor of IkappaB kinase 2, 
TPCA-1(2-[(aminocarbonyl)amino]-5-(4-fluorophenyl)-3-thiophenecarboxamide), occurs via 
reduction of proinflammatory cytokines and antigen-induced T cell proliferation, J. 
Pharmacol. Exp. Ther. 312 (2005) 373–381. 
[26] H. Hata, N. Sakaguchi, H. Yoshitomi, et al., Distinct contribution of IL-6, TNF-alpha, 
IL-1, and IL-10 to T cell-mediated spontaneous autoimmune arthritis in mice, J. Clin. Invest. 
114 (2004) 582–588. 
[27] Q. Li, I.M. Verma, NF-kappaB regulation in the immune system, Nat. Rev. Immunol. 2 
(2002) 725–734. 
[28] S.S. Makarov, NF-kappa B, in rheumatoid arthritis: a pivotal regulator of inflammation, 
hyperplasia, and tissue destruction, Arthritis Res. 3 (2001) 200–206. 
18 
 
[29] H. Asahara,M. Asanuma, N. Ogawa, et al., High DNA-binding activity of transcription 
factor NF-kappa B in synovial membranes of patients with rheumatoid arthritis, Biochem. 
Mol. Biol. Int. 37 (1995) 827–832. 
[30] S. Agrawal, R. Misra, A. Aggarwal, Autoantibodies in rheumatoid arthritis: association 
with severity of disease in established RA, Clin. Rheumatol. 26 (2007) 201–204. 
[31] S. Bas, T.V. Perneger, E. Mikhnevitch, et al., Association of rheumatoid factors and anti-
filaggrin antibodies with severity of erosions in rheumatoid arthritis, Rheumatology (Oxford) 
39 (2000) 1082–1088. 
[32] G.J. Silverman, J. Vas, C. Grönwall, Protective autoantibodies in the rheumatic diseases: 
lessons for therapy, Nat. Rev. Rheumatol. 9 (2013) 291–300. 
[33] W.H. Robinson, T.M. Lindstrom, R.K. Cheung, et al., Mechanistic biomarkers for 
clinical decision making in rheumatic diseases, Nat. Rev. Rheumatol. 9 (2013) 267–276. 
[34] M.W. Boulé, C. Broughton, F. Mackay, et al., Toll-like receptor 9-dependent and -
independent dendritic cell activation by chromatin–immunoglobulin G complexes, J. Exp. 
Med. 199 (2004) 1631–1640. 
[35] L.G. Francisco, M.V.A. Jose, G. Francisco, L. Rafael, M.V.J. Francisco, C.G.F. Juan, 
Intraarticular therapy of experimental arthritis with a derivative of triamcinolone acetonide 
incorporated in liposomes, J. Pharm. Pharmacol. 45 (1993) 576–578.  
[36] W.C. Foong, K.L. Green, The retention and distribution of dual-labeled liposomes 
injected into arthritic joints, Br. J. Pharmacol. 80 (1983) 522. 
[37] N.C. Phillips, P. Page-Thomas, C.G. Knight, J.T. Dingle, Liposome-incorporated 
corticosteroids. II. Therapeutic activity in experimental arthritis, Ann. Rheum. Dis. 38 (1979) 
553–557. 
[38] D.J. Burgess, S.S. Davis, Potential use of albumin microspheres as a drug delivery 
system. II. In vivo deposition and release of steroids, Int. J. Pharm. 46 (1988) 69–76. 
[39] K.E. Brown, K. Leong, C.-H. Huang, R. Dalal, G.D. Green,H.B. Haimes, P.A. Jimenez, 
J. Bathon, Gelatin/chondroitin 6-sulfate microspheres for the delivery of therapeutic proteins 
to the joint, Arthritis Rheum. 41 (1998) 2185–2195. 
[40] M.J. D'Souza, P. DeSouza, Preparation and testing of cyclosporine microsphere and 
solution formulations in the treatment of polyarthritis in rats, Drug Dev. Ind. Pharm. 24 
(1998) 841–852. 
[41] M. Tuncay, S. Calis, H.S. Kas, M.T. Ercan, I. Peksoy, A.A. Hincal, Diclofenac sodium 
incorporated PLGA (50:50) microspheres: formulation considerations and in vitro/in vivo 
evaluation, Int. J. Pharm. 195 (2000) 179–188. 
[42] C.H. Evans, V.B. Kraus, L.A. Setton, Progress in intra-articular therapy, Nat. Rev. 
Rheumatol. 10 (1) (2014) 11–22.  
19 
 
[43] N. Butoescu, O. Jordan, E. Doelker, Intra-articular drug delivery systems for the 
treatment of rheumatic diseases: a review of the factors influencing their performance, Eur. J. 
Pharm. Biopharm. 73 (2) (2009) 205–218. 
[44] D.A. Rothenfluh, H. Bermudez, C.P. O'neil, J.A. Hubbell, Biofunctional polymer 
nanoparticles for intra-articular targeting and retention in cartilage, Nat. Mater. 7 (2008) 
248–254. 
